Necrostatin-5
Based on 1 publication(s) in Google Scholar
Necrostatin-5 (Nec-5) is a potent necroptosis inhibitor with an EC50 value of 0.24 µM. Necrostatin-5 also is a RIP1 inhibitor. Necrostatin-5 shows cardioprotective effects.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 99.40%
- CAS No.: 337349-54-9
- 화학식: C19H17N3O2S2
- 분자량:383.49
-
보관:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) Necrostatin-5
More
Biological Activity
제품 설명
|
RIPK1 |
necroptosis 0.24 μM (EC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Jurkat | EC50 |
0.24 μM
Compound: Nec-15; N13
|
Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 38199165] |
| Jurkat | EC50 |
0.24 μM
Compound: Nec-5
|
Inhibition of TNF-alpha-induced necroptosis in FADD-deficient Jurkat T cells
Inhibition of TNF-alpha-induced necroptosis in FADD-deficient Jurkat T cells
|
[PMID: 17270434] |
| Jurkat | EC50 |
240 nM
Compound: 3
|
Inhibition of cellular necroptosis in TNFalpha treated FADD deficient human Jurkat cells
Inhibition of cellular necroptosis in TNFalpha treated FADD deficient human Jurkat cells
|
[PMID: 18408713] |
In Vitro
Necrostatin-5 (1, 5, 10, 50, 100 µM) inhibits LDH release in a dose-dependent mnner[3].
Necrostatin-5 (100 µM) protects MH-S cells against challenge with S. aureus, Listeria monocytogenes, S. pneumoniae, uropathogenic Escherichia coli (UPEC), and protectes against pneumolysin-induced death[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:200-300 g, male Wistar rats[2]
-
Dosage:2.46 mg/kg
-
Administration:I.p.; 60 min before experiment
-
Result:Reduced the infarction zone caused by 30-min global ischemia and 120-min reperfusion.
Chemical Information
-
CAS No. 337349-54-9
-
Appearance Solid
-
분자량 383.49
-
화학식 C19H17N3O2S2
-
Color White to off-white
-
SMILES
O=C(N1C2=CC=C(C=C2)OC)C3=C(N=C1SCC#N)SC4=C3CCCC4
-
Synonyms
Nec-5
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Biochem Biophys Res Commun
Engineered MAP30ER: A plant toxin-derived platform for EGFR-Targeted delivery of protein and chemotherapeutic payloads. [Abstract]2025 Aug 30:776:152184. PMID: 40517671
용액&용해도
In Vitro:
DMSO : 5 mg/mL (13.04 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
순도&문서
-
Data Sheet (278 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Wang K, et al. Structure-activity relationship analysis of a novel necroptosis inhibitor, Necrostatin-5. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1455-65. [Content Brief]
[2]. Dmitriev YV, et al. Study of cardioprotective effects of necroptosis inhibitors on isolated rat heart subjected to global ischemia-reperfusion. Bull Exp Biol Med. 2013 Jun;155(2):245-8. [Content Brief]
[3]. González-Juarbe N, et al. Pore-Forming Toxins Induce Macrophage Necroptosis during Acute Bacterial Pneumonia. PLoS Pathog. 2015 Dec 11;11(12):e1005337. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6076 mL | 13.0381 mL | 26.0763 mL | 65.1907 mL |
| 5 mM | 0.5215 mL | 2.6076 mL | 5.2153 mL | 13.0381 mL | |
| 10 mM | 0.2608 mL | 1.3038 mL | 2.6076 mL | 6.5191 mL |